Clinical trial of AAV8-mediated FVIII gene transfer for hemophilia A
AAV8 介导的 FVIII 基因转移治疗甲型血友病的临床试验
基本信息
- 批准号:10304874
- 负责人:
- 金额:$ 66.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-01-10 至 2023-11-30
- 项目状态:已结题
- 来源:
- 关键词:18 year oldAdultAdverse eventAffectAnimalsBiological AssayBloodBlood Coagulation DisordersBlood Coagulation FactorBody FluidsCapsidCapsid ProteinsClinicalClinical TrialsCoagulation ProcessCodon NucleotidesComplementary DNACystic FibrosisDNA cassetteDefectDependovirusDevelopmentDiagnosisDiseaseDoseDose-LimitingEmotionalEnzyme-Linked Immunosorbent AssayF8 geneFactor IXFactor IXaFactor VIIIFecesFrequenciesFutureGene DeliveryGene TransferGene therapy trialGenesGenomeGlycoproteinsGrantHealthHealth PersonnelHemophilia AHemophilia BHemorrhageHumanImage AnalysisImmune responseImmunosuppressionIncidenceKineticsLaboratoriesLifeLinkLiverLiver diseasesMacaca mulattaMediatingMethodsMonitorMusMutationNational Heart, Lung, and Blood InstituteNeurocognitiveParticipantPatient Outcomes AssessmentsPatientsPeripheralPhasePhase I/II Clinical TrialPhenotypePreventionProductionProteinsQuality of lifeRecombinant ProteinsRecombinant adeno-associated virus (rAAV)SafetySalivaSavingsSeminal fluidSerotypingSteroidsTestingTherapeuticThrombinTimeToxic effectTransgenesTransgenic OrganismsUrea cycle disordersUrineVeinsViral PackagingVirus Sheddingadeno-associated viral vectoralternative treatmentbasecohortdesignexperiencegene therapyimprovedinhibitorinsightinterestmouse modelneutralizing antibodynonhuman primatenovelnovel therapeutic interventionopen labelparticleprimary endpointpromoterprophylacticrecruittreatment durationvectorvector genome
项目摘要
Abstract
We propose an open label, dose-escalation, phase I/II study in which a single dose of the novel
recombinant AAV vector, AAV2/8 HLP FVIII-V3co, will be administered into a peripheral vein of
adult subjects with severe hemophilia A . Our premise is that this will be a safe and efficacious
approach for limiting the bleeding propensity of these patients . Hemophilia A (HA) is an X-linked
recessive bleeding disorder that results from a defect in the factor VIII (FVIII) gene. FVIII encodes a
glycoprotein procofactor which, when activated by thrombin, interacts with factor IXa in the coagulation
cascade, leading to clot formation. Clinically, the disease is characterized by frequent spontaneous
bleeding, which can be life-threatening. There are several novel aspects to our approach to liver-targeted
AAV-mediated FVIII gene transfer, including 1) a unique FVIII cDNA that meets the size constraints of AAV
and mediates synthesis of fully functional FVIII protein, 2) an expression cassette that improves the efficiency
of FVIII expression and secretion and 3) an improved method of recombinant AAV vector production. Our
extensive studies in murine models and rhesus macaques have shown that AAV2/8 HLP FVIII-V3co vector
safely establishes therapeutic levels of FVIII in these animals. In addition, we now have the unique
experience of having conducted a successful phase I/II clinical trial of liver-targeted, AAV-mediated FIX gene
transfer for hemophilia B that has provided new insights to the design of our AAV-mediated FVIII gene transfer
trial. We propose to test three dose levels: 6x1011, 2x1012 and 6x1012 vg/kg. The primary objective of the
study is to assess the safety of systemic administration of this vector while the secondary objectives are:
1) to determine the dose of vector particles required to achieve stable expression of FVIII ≥5% of normal; 2)
to explore the impact on quality of life, emotional health and neurocognitive function; 3) to describe the
immune responses to the FVIII transgene product and AAV capsid proteins and 4) to assess viral shedding
into various body fluids. Recruitment will be limited to adults (≥18 years of age) with a confirmed diagnosis
of severe HA caused by a mutation in the FVIII gene not associated with a high incidence of inhibitor
formation. In addition, participants must have had ≥50 exposure days of treatment with FVIII protein
concentrate without having developed an inhibitor. Dose escalation will proceed based on safety (primary)
and efficacy (secondary) criteria. Immunosuppression will not be given routinely to patients receiving the
lowest dose of vector; rather, only for those low dose patients who develop ALT elevation >1.5-times
baseline. However, based on our AAV2/8 FIX experience, all patients in the intermediate and high dose
cohorts will receive prophylactic steroids from weeks 6-13. Stopping rules are in place which include: 1) the
occurrence of Grade IV or V toxicity in one patient or Grade III toxicity in two patients at a given dose level or
2) the development of neutralizing antibodies to FVIII in one patient.
摘要
我们提出了一个开放标签,剂量递增,I/II期研究,其中单剂量的新的
重组AAV载体AAV 2/8 HLP FVIII-V3 co将被施用到患者的外周静脉中。
重度血友病A成人受试者。我们的前提是,这将是一个安全有效的
限制这些患者出血倾向的方法。血友病A(HA)是一种X-连锁
一种由凝血因子VIII(FVIII)基因缺陷引起的隐性出血性疾病。FVIII编码
一种糖蛋白原辅因子,当被凝血酶激活时,与凝血因子IXa相互作用
级联,导致凝块形成。临床上,该病的特点是频繁自发性
出血,可能危及生命。我们的肝脏靶向治疗方法有几个新颖的方面,
AAV介导的FVIII基因转移,包括1)符合AAV大小限制的独特FVIII cDNA
并介导全功能FVIII蛋白的合成,2)提高效率的表达盒,
和3)重组AAV载体生产的改进方法。我们
在鼠模型和恒河猴中的广泛研究表明,AAV 2/8 HLP FVIII-V3 co载体
在这些动物中安全地确定FVIII的治疗水平。此外,我们现在拥有独特的
成功开展肝脏靶向、AAV介导的FIX基因I/II期临床试验的经验
这为我们设计AAV介导的FVIII基因转移提供了新的见解
审判我们建议测试三个剂量水平:6x 1011、2x 1012和6x 1012 vg/kg。的主要目的
本研究旨在评估该载体全身给药的安全性,而次要目的是:
1)确定实现FVIII稳定表达所需的载体颗粒剂量≥正常值的5%; 2)
探讨对生活质量、情绪健康和神经认知功能的影响; 3)描述
对FVIII转基因产物和AAV衣壳蛋白的免疫应答和4)评估病毒脱落
变成各种体液招募仅限于确诊的成人(≥18岁)
由FVIII基因突变引起的重度HA与抑制剂的高发生率无关
阵此外,受试者必须接受≥50天的FVIII蛋白治疗暴露
浓缩而不产生抑制剂。将根据安全性(主要)进行剂量递增
和功效(次要)标准。免疫抑制剂将不常规给予接受
最低剂量的载体;相反,仅适用于发生ALT升高>1.5倍的低剂量患者
基线。然而,根据我们的AAV 2/8 FIX经验,中等和高剂量组的所有患者均接受了治疗。
队列将从第6-13周接受预防性类固醇治疗。停止规则包括:1)
在给定剂量水平下,1例患者发生IV级或V级毒性,或2例患者发生III级毒性,或
2)1例患者出现FVIII中和抗体。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANDREW M DAVIDOFF其他文献
ANDREW M DAVIDOFF的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANDREW M DAVIDOFF', 18)}}的其他基金
Clinical trial of AAV8-mediated FVIII gene transfer for hemophilia A
AAV8 介导的 FVIII 基因转移治疗甲型血友病的临床试验
- 批准号:
10063895 - 财政年份:2018
- 资助金额:
$ 66.93万 - 项目类别:
ANGIOGENESIS INHIBITORS IN THE MULTIMODAL TREATMENT OF PEDIATRIC SOLID TUMORS
血管生成抑制剂在小儿实体瘤多模式治疗中的应用
- 批准号:
8309814 - 财政年份:2011
- 资助金额:
$ 66.93万 - 项目类别:
Strategies to improve the antiglioma action of IFN-?: a role for NF-kB inhibition
改善 IFN-α 抗神经胶质瘤作用的策略:抑制 NF-kB 的作用
- 批准号:
8020141 - 财政年份:2009
- 资助金额:
$ 66.93万 - 项目类别:
Clinical trial of self complementary AAV8-mediated gene transfer for hemophilia B
自我互补 AAV8 介导的基因转移治疗 B 型血友病的临床试验
- 批准号:
7565700 - 财政年份:2009
- 资助金额:
$ 66.93万 - 项目类别:
Clinical trial of self complementary AAV8-mediated gene transfer for hemophilia B
自我互补 AAV8 介导的基因转移治疗 B 型血友病的临床试验
- 批准号:
8231434 - 财政年份:2009
- 资助金额:
$ 66.93万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 66.93万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 66.93万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 66.93万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 66.93万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 66.93万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 66.93万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 66.93万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 66.93万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 66.93万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 66.93万 - 项目类别:
Grant-in-Aid for Scientific Research (C)